A liquid biopsy is an advanced, non-invasive diagnostic method that detects cancer and other diseases through a simple blood or bodily fluid sample¹.

Liquid biopsy provides a faster, less invasive alternative to traditional tissue biopsies by analyzing components like circulating tumor DNA (ctDNA), exosomes, and circulating tumor cells (CTCs). Liquid biopsies enable early detection, real-time monitoring of treatment response, and tracking of disease progression, making them an essential tool in precision oncology².

In contrast, conventional tissue biopsies require the surgical removal of solid tumor samples, which can be invasive, time-consuming, and carry risks such as infection or sampling errors due to tumor heterogeneity. With advancements in medical technology, liquid biopsies, also known as liquid biopsies, have emerged as a transformative approach in cancer diagnostics^3,4. They reduce complications, allow ongoing monitoring, and can more efficiently detect signs of treatment resistance or disease recurrence.

While not yet universally definitive, especially in early-stage cancer detection, continuous innovation is improving the sensitivity and reliability of liquid biopsies. As a result, they are rapidly becoming a vital complement to traditional diagnostics in personalized cancer care.

How does liquid biopsy work?

Standardized collection protocols ensure biomarker stability during sample processing. Optimized techniques like centrifugation, filtration, and cellular component isolation help concentrate and extract biomarkers efficiently.

By enhancing screening and diagnostic efficiency, liquid biopsy helps improve diagnostic accuracy and reduce healthcare costs. Advancements in the technique, including a multi-step DNA extraction process, (cell lysis, separation of soluble DNA, binding to a purification matrix, and removal of contaminants) to ensure purity and integrity has improved the sensitivity and specificity of liquid biopsy⁶. These steps are vital for obtaining accurate genetic insights that guide personalized cancer treatment.

Liquid biopsies offer several advantages, including the ability to⁵:

• Monitor tumor dynamics in real-time
• Detect minimal residual diseases
• Identify emerging resistance mechanisms

Techniques used in liquid biopsy

Liquid biopsy techniques include methods like next-generation sequencing (NGS), digital PCR (dPCR), and BEAMing, which aid in detecting genetic alterations in circulating tumor DNA (ctDNA)⁷.

Next-generation sequencing (NGS)

NGS is a powerful tool for liquid biopsy, enabling high-throughput analysis of genetic changes and biomarkers⁸. Targeted sequencing panels enhance this process by capturing specific DNA fragments for NGS analysis, allowing the detection of mutations, amplifications, and fusions linked to cancer. These panels provide a cost-effective approach for analyzing various cancers, including lung, breast, and colorectal cancer. Examples of NGS include:

• Whole-exome sequencing (WES) scans the protein-coding areas of the genome to detect known and novel genetic mutations in liquid biopsy samples. It helps identify treatable mutations and supports personalized therapeutic planning.
• Single-cell sequencing enables detailed analysis of individual tumor cells from liquid biopsy samples, revealing rare subpopulations and genetic changes. This approach provides insights into intra-tumoral heterogeneity, clonal evolution, and tumor progression.
• Whole genome sequencing (WGS) scans the entire genetic makeup, detecting mutations, structural abnormalities, and genomic rearrangements in liquid biopsy samples. It provides a comprehensive view of tumor evolution and genetic heterogeneity, aiding in personalized treatment planning.
• NGS-based methylation profiling detects epigenetic alterations associated with cancer development and progression. Identifying abnormal methylation patterns in specific genes or regions can help establish biomarkers for cancer diagnosis and prognosis.
• Fusion gene detection arising due to chromosomal rearrangements is common in cancers. NGS-based methods in liquid biopsy help uncover tumorigenesis-related genomic changes, aiding cancer diagnosis, classification, and treatment selection.

Droplet digital polymerase chain reaction (ddPCR)

Droplet digital PCR provides precise and absolute quantification of nucleic acids by partitioning the PCR reaction into thousands of microdoplets⁸. ddPCR serves as a digital alternative to traditional quantitative (qPCR) PCR, offering advantages for liquid biopsy analysis. Unlike conventional PCR, ddPCR enhances sensitivity and accuracy by amplifying individual template molecules in separate reactions.

For example, droplet digital PCR (ddPCR) has emerged as a highly sensitive and precise method for detecting nucleic acid-based biomarkers in liquid biopsies, significantly enhancing cancer diagnostics⁹. This technology enables the quantification of genetic alterations such as mutations, copy number variations, and gene rearrangements in circulating tumor DNA (ctDNA) and RNA (ctRNA) obtained from non-invasive samples like blood, plasma, and saliva.

The ultra-sensitive nature of ddPCR allows for the detection of minimal residual disease and early relapse by identifying low-frequency mutations that traditional methods might miss. Its application extends across various malignancies, including lung, colorectal, and breast cancer, facilitating real-time monitoring of tumor dynamics and treatment responses.

Moreover, the ability of ddPCR to analyze alternative biological fluids, such as cerebrospinal fluid, urine, and saliva, broadens its utility in cases where blood samples are insufficient or infeasible. By providing rapid and accurate molecular insights, ddPCR plays a vital role in guiding therapeutic decisions and improving patient outcomes.

Beads, emulsification, amplification, and magnetics (BEAMing)

BEAMing is a modified form of emulsion PCR that allows the amplification of multiple templates within a single tube⁷. This technology is used as a liquid biopsy method that enables the non-invasive analysis of tumor genotypes by detecting in blood.

The process involves

1. DNA isolation and PCR amplification of target regions.
2. Binding amplified sequences to magnetic beads within water-oil emulsion microdroplets.
3. Purification, fluorophore staining (to distinguish mutant vs. wild-type sequences), and flow cytometry analysis to quantify mutations.

Key biomarkers analyzed

A biomarker is an indicator of normal biological processes, disease progression, or responses to treatment or exposure. Liquid biopsies enable the detection and analysis of tumor-derived biomarkers in biofluids, providing essential insights into the genetic and molecular characteristics of cancer⁶. Some of the most common biomarkers are discussed below.

Circulating tumor DNA (ctDNA)

Circulating tumor DNA (ctDNA) is fragmented DNA released by tumor cells into the blood, carrying the same genetic mutations as the original tumor. Liquid biopsy using ctDNA analysis has shown high sensitivity and specificity for diagnosing, monitoring, and detecting cancer, including at early stages. ctDNA analysis is a highly sensitive and specific noninvasive method that can enhance tumor diagnosis, including early detection¹⁰.

It accurately assesses tumor progression, prognosis, and aids in targeted therapy. With advancements in the cancer genome project (CGP) and NGS, ctDNA-based liquid biopsy is expected to revolutionize cancer diagnosis, prognosis, and treatment.

Circulating tumor cells (CTCs)

CTCs are intact, viable tumor cells that detach from primary tumors and enter the bloodstream or lymphatic system, potentially causing metastases. Their detection relies on molecular markers like epithelial cell adhesion molecules (EpCAM), primarily used for cancers such as breast and prostate. However, their low concentration in blood makes identification challenging. Due to their variability across cancer types and stages, CTCs have limited utility for early detection, requiring highly sensitive technologies for effective isolation and analysis.

Several methods exist for the positive enrichment of CTCs. For example, one approach uses antibody-coated beads specific to cancer types, followed by real-time polymerase chain reaction (PCR) to analyze gene expression¹¹. Other techniques, such as magnetic-activated cell sorting (MACS) and immunomagnetic enrichment, utilize magnetic nanoparticles or automated magnetic rods to capture CTCs.

Cell-free DNA (cfDNA)

Cell-free DNA (cfDNA) is fragmented DNA found in biofluids, released from both normal and tumor cells through apoptosis, necrosis, and active secretion from tumors. cfDNA is present in various body fluids like blood, urine, and saliva, with higher concentrations detected during inflammation, surgery, or trauma. It has become a valuable biomarker used in prenatal testing, immune disease detection, organ transplant monitoring, and cancer diagnosis.

Extracellular vesicles (EVs) and exosomes

Extracellular vesicles (EVs) are small, membranous particles found in bodily fluids, playing a key role in intercellular communication by regulating various physiological and pathological processes. They are classified into exosomes, microvesicles, and apoptotic bodies, each differing in size, content, and function, and they transport biomolecules like proteins, lipids, RNA, and DNA. Exosomes, a subset of EVs, are enriched in tumor-specific miRNAs and proteins, making them promising diagnostic tools. Since EVs from cancer patients carry tumor-derived molecules, they are being explored as potential cancer biomarkers for diagnosis and monitoring.

Tumor-educated platelets (TEPs)

Platelets are small, non-nucleated cell fragments produced by megakaryocytes, primarily involved in blood clot formation and wound healing. In cancer, tumor-educated platelets (TEPs) undergo molecular changes due to interactions with tumor cells, contributing to tumor progression and metastasis. These altered platelets serve as potential liquid biopsy biomarkers for detecting cancers like non-small cell lung cancer (NSCLC), glioblastoma (GBM), and sarcoma. TEPs are analyzed by sequencing RNA or proteins in their cargo, which reflect tumor-derived alterations.

Circulating cell-free RNA (cfRNA)

Cell-free RNA (cfRNA) consists of degraded RNA fragments released into the bloodstream by apoptotic or necrotic cells, with circulating tumor RNA (ctRNA) specifically originating from cancer cells. It includes subtypes like mRNA, miRNA, and lncRNA, with miRNA being a stable biomarker for cancer detection. Unlike DNA, RNA is highly unstable, with a short half-life of about 15 seconds in plasma. This instability poses a major challenge for ctRNA analysis, and an optimal extraction method has yet to be established. Stabilization techniques, such as RNase inhibitors and rapid processing, are important to preserve RNA integrity during analysis¹².

Recent research has revealed a complex and dynamic relationship between microbes and tumor progression. The microbiota-including bacteria residing within tumors-interacts closely with the tumor microenvironment, collectively influencing cancer initiation, progression, metastasis, and response to therapy. These microbial communities can modulate immune responses, alter metabolic pathways, and even affect the efficacy of cancer treatments. Liquid biopsy technologies now enable the non-invasive detection of microbial biomarkers, such as circulating microbial DNA and microbial extracellular vesicles, in bodily fluids. These microbial signatures hold promise not only for early cancer diagnosis but also for predicting treatment responses and patient prognosis, highlighting the vital role of microbes in tumor biology and clinical oncology.

Types of liquid biopsies

Liquid biopsies can be of different types based on the sample type used. The diversity of samples used increases the likelihood of successful cancer detection.

Blood (plasma, serum)

While plasma ctDNA analysis has shown promise in predicting patient outcomes, challenges arise from high levels of cfDNA in white blood cells, making detection more difficult compared to non-blood samples¹³.

Urine

Urine samples can be used to detect metabolites and proteins associated with various diseases.

Urine is an ideal, cost-effective, and non-invasive source for liquid biopsy, commonly used in urine cytology and urinary tumor biomarkers. This non-invasive strategy holds promise for improving early detection, prognosis, and personalized treatment planning in cancer management¹³.

Cerebrospinal fluid (CSF)

CSF’s low cellularity reduces background noise for detecting tumor genomic material, with studies showing higher yields in CSF compared to plasma samples.

A case report described a lung adenocarcinoma patient who developed neurological symptoms during treatment. Initial magnetic resonance imaging (MRI) and CSF cytology were negative for brain metastasis. However, CSF ctDNA analysis identified the same EGFR mutation found in the patient’s lung tumor. Follow-up MRI confirmed brain metastasis, suggesting CSF ctDNA could be an early diagnostic biomarker, potentially detecting brain metastasis before traditional tests like MRI or cytology.

Although obtaining CSF is more invasive than blood, it offers key advantages, such as capturing information specific to CNS metastases that may not be detected in plasma due to the blood-brain barrier¹⁴.

Saliva

Saliva contains DNA, RNA, proteins, exosomes, and other molecules that can serve as biomarkers for various diseases, including oral cancers and systemic conditions¹⁵.

For example, saliva-based diagnostic tests are ideal for head and neck squamous cell carcinoma (HNSCC) diagnosis due to their non-invasive, safe, sensitive, and cost-effective nature.

Pleural fluid and ascites

Pleural fluid (from the pleural cavity) and ascitic fluid (from the abdominal cavity) can accumulate due to malignancies, infections, or other conditions. Analyzing these fluids through liquid biopsy can help detect cancer cells, ctDNA, and other biomarkers¹⁶.

For example, studies have shown that this liquid biopsy approach significantly improves the detection of epidermal growth factor receptor (EGFR) mutations, including the T790M resistance mutation, in patients with pulmonary adenocarcinoma. This method is particularly valuable when tumor tissue is not easily accessible, providing critical information for targeted therapy decisions¹⁷.

Biomarker detection

ctDNA analysis

Due to its often-low concentration and the presence of normal cfDNA interference, sensitive detection methods are essential. Techniques include qPCR, dPCR, ddPCR, BEAMing, and various NGS approaches like TAm-Seq, CAPP-Seq, Whole genome sequencing (WGS), and WES. While ctDNA is widely distributed in body fluids and detection techniques are becoming more standardized, further clinical trials are needed to validate its therapeutic application value, and standardizing detection processes remains a challenge¹⁸,¹⁹.

CTC analysis

CTCs represent a highly heterogeneous population and are present in peripheral blood in extremely low numbers, making their detection and isolation technically challenging. Microfluidic platforms and immunomagnetic separation are notable technological advancements in this area ¹⁸,¹⁹.

Exosome-based liquid biopsy

The presence of EVs, often in substantial concentrations, makes them attractive targets for minimally invasive liquid biopsies. Cancer-derived EVs and their cargo, like specific miRNAs or proteins, show promise as diagnostic and prognostic biomarkers. Detection methods for exosomal contents include techniques like RT-PCR, genome sequencing, and proteomics. Effective extraction and purification methods are critical steps for EV research and application, with common techniques including ultracentrifugation, size exclusion chromatography (SEC), polymer precipitation, immunoaffinity capture, and microfluidics¹⁸,¹⁹.

Applications of liquid biopsy in cancer care

Liquid biopsy is used in cancer care for early detection, real-time monitoring of tumor progression, and assessment of treatment response. It also helps in identifying genetic mutations for targeted therapy and predicting patient prognosis. Below is a detailed explanation of the applications of liquid biopsy in cancer care²⁰.

Early cancer detection and screening

Early detection of cancer significantly improves patient outcomes. Liquid biopsies offer a noninvasive method to identify malignancies during the initial stages of tumor development by detecting ctDNA and other biomarkers in blood samples. These approaches help reduce cancer mortality and are particularly advantageous for cancers lacking effective screening methods, as they allow for the detection of tumors before they become symptomatic. However, challenges such as achieving sufficient sensitivity and specificity for early-stage cancers remain.

Comparison of liquid biopsy for early detection of cancer

Liquid biopsy applications vary across different cancer types. They enable repeated tracking of tumor evolution and provide a better assessment of intra-tumor heterogeneity compared to single tissue biopsies. For instance, in ovarian cancer, traditional biomarkers like CA-125 have low predictive value and high false-positive rates. Liquid biopsy-based assessment of EVs presents a novel approach for early detection and treatment monitoring, potentially improving overall survival rates.

Tumor profiling for personalized treatment

Understanding the molecular profile of a tumor is vital for selecting appropriate therapies. Liquid biopsies enable the detection of genomic and transcriptomic alterations in ctDNA, providing a comprehensive characterization of tumor heterogeneity. This real-time molecular information facilitates personalized treatment strategies, allowing clinicians to tailor therapies to the specific genetic mutations present in a patient’s cancer.

Treatment monitoring

Monitoring treatment efficacy is essential for optimizing therapeutic regimens. Liquid biopsies offer a minimally invasive means to assess tumor dynamics by quantifying ctDNA levels over time. Fluctuations in ctDNA concentrations can indicate treatment response or emerging resistance, enabling timely adjustments to treatment plans. This approach provides a real-time assessment of tumor burden without the need for repeated invasive tissue biopsies.

Minimal residual disease (MRD) detection

Minimal residual disease (MRD) refers to residual tumor cells undetectable by traditional methods or imaging. Liquid biopsy can detect MRD by analyzing CTCs, ctDNA, tumor-specific miRNA, and DNA methylation patterns in the blood.

Detecting MRD is vital for identifying patients at risk of relapse. Liquid biopsy assays can identify trace amounts of tumor DNA that persist after treatment, serving as a predictive biomarker for MRD. Epigenetic changes in ctDNA are emerging as sensitive markers for MRD detection, offering a promising tool for future research. Serial ctDNA assessment helps evaluate the effectiveness of chemotherapy, radiation, or surgery by detecting MRD early.

Monitoring of cancer recurrence

Regular surveillance for cancer recurrence is important for early intervention. Serial ctDNA analysis helps detect emerging resistance to targeted therapies, predict prognosis in metastatic cancers, and assess the efficacy of chemotherapy, radiation, or surgery. This dynamic approach allows timely adjustments in treatment plans, improving clinical outcomes. The non-invasive nature of liquid biopsies makes them suitable for frequent sampling, providing detailed insights into a patient’s disease status.

Advantages of liquid biopsy

Liquid biopsies enable non-invasive extraction and analysis of tumor-derived biomarkers, aiding in early cancer detection, predicting and overcoming drug resistance, and guiding personalized treatment. They offer the following advantages:

Non-invasive nature

Liquid biopsy is a non-invasive method that minimizes procedural risks such as bleeding, infection, and discomfort, particularly benefiting patients with advanced cancers or those ineligible for invasive interventions³. It eliminates the need for surgical procedures or needle aspirations like tissue biopsy. For example, in metastatic lung cancer, repeated tissue biopsies are often impractical due to tumor inaccessibility or patient frailty; liquid biopsies provide a safer alternative for continuous monitoring ²¹.

Real-time monitoring

Liquid biopsy provides real-time insights into tumor dynamics, which is essential due to the temporal and spatial heterogeneity of tumors. Unlike traditional biopsies that analyze predominant tumor cells, cfDNA-based liquid biopsy captures genetic information from all tumor sites⁵. This allows for more accurate monitoring of disease burden, progression, and tumor heterogeneity, enabling timely treatment adjustments.

Comprehensive tumor profiling

By analyzing ctDNA and CTCs, liquid biopsies provide a comprehensive view of tumor heterogeneity. They detect a wide range of genetic mutations and alterations present within different tumor subclones²². Such detailed profiling is vital for selecting targeted therapies and understanding the molecular underpinnings of an individual’s cancer.

Faster results

Liquid biopsy provides faster results as the processing time is shorter. This enables rapid cancer diagnosis compared to traditional biopsy methods²⁰. Point-of-care diagnostics can deliver results in under 30 minutes, allowing healthcare workers to make quick clinical decisions. Additionally, microbial cfDNA sequencing improves infection management by identifying pathogens in sepsis faster and with higher detection rates than standard blood cultures.

Potential for cost-effectiveness

Liquid biopsy enables early cancer detection, potentially reducing the financial burden associated with late-stage (III/IV) cancer, which requires prolonged hospital stays, frequent outpatient visits, and emergency admissions⁶. By improving early diagnosis, liquid biopsy enhances patient outcomes while lowering overall healthcare costs.

Challenges and limitations of liquid biopsy

Despite offering numerous advantages, liquid biopsy faces technical and regulatory challenges that hinder its widespread adoption. Some of the challenges are listed below.

Sensitivity and specificity concerns

Many liquid biopsies for early cancer detection lack sufficient sensitivity, as tumor-derived genetic biomarkers are often absent or present at undetectable levels in biofluids. For example, protein biomarkers like prostate-specific antigen (PSA) and carcinoma antigen-125 (CA-125) may not be elevated in cancer patients or can be elevated in non-cancerous conditions, reducing their specificity⁶. To improve early cancer detection, technologies must simultaneously analyze tumor-derived signals and account for non-cancer confounding factors for more reliable results.

Tumor heterogeneity and variability

Tumor heterogeneity and variability arise from genetic and environmental factors^23,24. Increasing detection complexity due to inconsistent histological and hematological results. It also introduces variations in tumor progression, further complicating accurate detection. Liquid biopsies provide a snapshot of the tumor’s status at a specific time point, which may not capture ongoing evolutionary changes, thereby limiting treatment decisions. The concentration of ctDNA and CTCs in the bloodstream can be exceedingly low, especially in early-stage cancers, making detection and analysis difficult²⁵.

Standardization issues

The absence of standardized protocols for liquid biopsy sample collection, processing, and analysis affects result accuracy and reproducibility. Differences in pre-analytical (eg, sample handling) and analytical (eg, sequencing) methods can lead to inconsistencies in diagnostic outcomes⁸. Standardized procedures are essential for ensuring reliable, cross-laboratory comparability.

Regulatory and clinical validation hurdles

Regulatory strategies for diagnostics of liquid biopsy involve stringent criteria set by agencies like the U.S. Food and Drug Administration (FDA). Challenges include demonstrating analytical validity (test accuracy), clinical validity (association with disease), and clinical utility (improved outcomes), as well as ensuring compliance with manufacturing and quality control standards²⁶.

Beyond analytical validity, it is vital to prove that liquid biopsy tests provide clinically actionable insights that improve patient outcomes²⁷. This requires extensive clinical trials to correlate test results with clinical endpoints, such as therapeutic response, progression-free survival, and overall survival.

Cost of advanced technologies

The high cost of liquid biopsy, including sample processing and specialized laboratory techniques, limits its widespread adoption. Advanced technologies like NGS require significant infrastructure and expertise, adding to the expense⁸. To integrate liquid biopsy into routine clinical practice, its cost-effectiveness must align with its therapeutic benefits.

Current status of liquid biopsy technologies

Ongoing research focuses on improving sensitivity, specificity, and standardization to enhance their clinical utility in early detection and personalized treatment.

FDA-approved liquid biopsy tests

Several liquid biopsy tests are approved by the FDA and use liquid biopsy techniques, such as NGS for ctDNA or CTC enumeration, while some are still in clinical trial stages. Some of these tests are listed below:

• In 2016: PCR-based liquid biopsy test for detecting epidermal growth factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations in NSCLC. This helps in detecting the exact location of mutations and allows patients to receive treatments with EGFR tyrosine kinase inhibitors ²⁸. This approval revolutionized NSCLC management by establishing liquid biopsy as a reliable alternative to tissue biopsies.
• In 2020: Liquid biopsy NGS-based test for detecting multiple biomarkers in cell-free DNA from plasma samples²⁹,³⁰. The test serves as a companion diagnostic to identify mutations in BRCA1, BRCA2, ALK, PIK3CA, and ATM genes, aiding in targeted treatments for ovarian, lung, breast, and prostate cancers.
• In the same year, a pan-cancer liquid biopsy for guide targeted therapy for NSCLC, colorectal, and breast cancers by identifying key mutations like EGFR T790M, KRAS, NRAS, and HER2³¹.

Advances in biomarker detection

Recent advances in sensor technologies have improved biomarker detection sensitivity and specificity:

• Electrochemical biosensors incorporating nanoparticles or nanocomposites enhance sensitivity and dynamic range, improving diagnostic accuracy.
• Ultra-sensitive methods like digital ELISA and immunoprecipitation-mass spectrometry detect biomarkers at femtomolar concentrations, enabling early disease detection.
• Portable biosensors allow point-of-care testing in resource-limited settings. These devices analyze biofluids (eg, saliva, blood) with minimally invasive sampling, enhancing patient compliance³².

Emerging technologies

• Microfluidic devices: Automate CTC isolation via inertial focusing and antigen-specific antibodies, enabling efficient single-cell sequencing³³. Exosome isolation chips with nanoporous membranes and aptamers achieve high-purity miRNA profiling³⁴.
• Priming agents: Pharmacological agents (eg, DNA methyltransferase inhibitors) temporarily boost ctDNA shedding, improving detection rates in early-stage lung and liver cancers³⁵.
• Optical sensors: Quantum dots and graphene oxide-based sensors detect single ctDNA mutations with near-perfect specificity, outperforming traditional sequencing³⁶. Electrochemical aptasensors enable ultra-sensitive exosomal miRNA detection for point-of-care us³⁷,³⁸.
• AI-driven platforms: Machine learning models trained on ctDNA methylation, exosomal proteins, and CTC morphology classify tumor subtypes and predict treatment responses, reducing reliance on empirical methods³⁸.

Multi-cancer early detection (MCED)

Multi-cancer early detection (MCED) assays enable the simultaneous screening of multiple cancers from a single liquid biopsy by analyzing tumor-derived biomarkers. These tests have shown promising sensitivity and specificity in detecting cancers before symptom onset, even in those without existing screening protocols. However, challenges such as improving accuracy, addressing ethical concerns, and integrating MCED into healthcare systems remain hurdles³⁹.

Ongoing global clinical trials are assessing the efficacy, safety, and feasibility of MCED tests to determine their clinical applicability. These tests have the potential to transform cancer screening by detecting multiple cancers through a single blood draw.

For example, a multi-biomarker test identified 83% of colorectal cancer cases. It demonstrated improved early colorectal cancer detection by analyzing genomic mutations, methylation, and DNA fragmentation patterns. Its success highlights the potential for expanding similar approaches to detect multiple cancers through liquid biopsy.

Future directions in liquid biopsy research

Future research in liquid biopsy aims to enhance sensitivity and specificity for early cancer detection and MRD detection. Advances in multi-omics approaches and artificial intelligence integration will further improve its clinical applications and predictive capabilities.

Expanding applications beyond cancer

While liquid biopsy is predominantly used in oncology, its potential extends to other medical fields:

• Transplant rejection: Analysis of donor-derived cell-free DNA (dd-cfDNA) in blood plasma offers a non-invasive alternative to biopsies for detecting graft injury in kidney and liver transplants⁴⁰. Elevated dd-cfDNA levels correlate with rejection, enabling early intervention.
• Autoimmune diseases: Cell-free DNA (cfDNA) levels are elevated in rheumatoid arthritis and systemic lupus erythematosus, correlating with disease activity⁴¹. This suggests cfDNA could aid in diagnosis and monitoring, reducing reliance on invasive methods.

Integration with other diagnostic tools

Combining liquid biopsy with existing diagnostic modalities  enhance disease detection Imaging: A study showed that combining extracellular vesicle long RNA (evlRNA) profiles with CT radiomics improved AUC to 94.8% for distinguishing benign and malignant lung nodules⁴². Circulating tumor cell (CTC) counts correlated with PET-CT findings to stratify metastatic risk, reducing unnecessary biopsies⁴².

Cost reduction and accessibility

Liquid biopsy adoption is hindered by high costs. For example, in colorectal cancer screening, liquid biopsy combined with colonoscopy increases life-years but is less cost-effective compared to colonoscopy alone. Due to high incremental cost-effectiveness ratio (ICER)⁴³.

Future research aims to develop more cost-effective technologies (eg portable biosensors and wearables) and streamline protocols. Collaboration among researchers, clinicians, and policymakers is vital to ensure global accessibility.

Ongoing clinical trials

Clinical trials are evaluating liquid biopsy for:

• MCED: Plasma-based assays analyze ctDNA to detect cancers in asymptomatic individuals³⁹.
• MRD monitoring: Trials assess ctDNA’s utility in post-treatment surveillance.
• Treatment response: Studies correlate ctDNA dynamics with therapy outcomes.

MCED trials have shown promising sensitivity for detecting cancers lacking screening protocols. However, advanced bioinformatics tools are needed to improve accuracy.

FAQs

How does liquid biopsy compare to traditional tissue biopsy?

Liquid biopsy is a less invasive and quicker alternative to traditional tissue biopsy, as it requires only a blood or fluid sample instead of surgical tissue extraction. While tissue biopsy provides direct tumor analysis and is more accurate for initial diagnosis, liquid biopsy allows for real-time monitoring of tumor evolution and treatment response. However, liquid biopsy may have lower sensitivity for certain cancers, making it most effective when used alongside traditional methods.

Can liquid biopsy detect all types of cancer?

Liquid biopsy has shown promise in detecting many types of cancer, but its accuracy varies depending on the cancer type and stage. It is more effective for cancers that shed significant amounts of circulating tumor DNA (ctDNA) into the bloodstream, such as lung, breast, and colorectal cancers, but less effective for tumors with low ctDNA levels, like brain and early-stage cancers. Ongoing research aims to improve sensitivity and expand its application to a broader range of cancers.

How accurate are liquid biopsy tests compared to other diagnostic methods?

Liquid biopsy tests are highly sensitive and specific but may not always match the accuracy of traditional tissue biopsies, especially for detecting early-stage cancers or tumors with low circulating tumor DNA (ctDNA). While they offer advantages in monitoring treatment response and detecting minimal residual disease (MRD), false negatives can occur due to insufficient ctDNA in the bloodstream. Combining liquid biopsy with imaging and tissue biopsy improves overall diagnostic accuracy.

References

1. World Health Organization (WHO). Cancer. World Health Organization. (2023).
2. National Cancer Institute (NIH). What Is Cancer? National Cancer Institute. (2023).
3. Ziv, E., Durack, J. C. & Solomon, S. B. The Importance of Biopsy in the Era of Molecular Medicine.  The Cancer Journal.  22, 418–422 (2016).
4. Saini, A., Kumar, V., Chawla, Y. et al. Liquid Biopsy in Gastrointestinal Cancers.  Diagnostics  8, 75 (2018).
5. Ma, L., Zhou, J., Yang, H. et al. Liquid biopsy in cancer: current status, challenges and future prospects.  Signal Transduction and Targeted Therapy  9, 336 (2024).
6. Connal, S., Cameron, J. M., Sala, A. et al. Liquid biopsies: the future of cancer early detection.  Journal of Translational Medicine  21, 118 (2023).
7. Remon, J., García-Campelo, R., de Álava, E. et al. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.  Clinical and Translational Oncology  22, 823–834 (2020).
8. Shegekar, T., Vodithala, S. & Juganavar, A. The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy.  Cureus  15, e43650 (2023).
9. Olmedillas-López, S., Olivera-Salazar, R., García-Arranz, M. et al. Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review.  Molecular Diagnosis & Therapy  26, 61–87 (2022).
10. Cheng, F., Su, L. & Qian, C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.  Oncotarget  7, 48832–48841 (2016).
11. Nikanjam, M., Kato, S. & Kurzrock, R. Liquid biopsy: current technology and clinical applications.  Journal of Hematology & Oncology  15, 131 (2022).
12. Luo, F., Wang, X., Ye, C. et al. Microbial Biomarkers in Liquid Biopsy for Cancer: An Overview and Future Directions.  Cancer Control  31, 10732748241292019 (2024).
13. Ge, Q., Zhang, Z.-Y., Li, S.-N. et al. Liquid biopsy: Comprehensive overview of circulating tumor DNA.  Oncology Letters  28, 548 (2024).
14. Diaz, M., Chudsky, S., Pentsova, E. et al. Clinical applications of cerebrospinal fluid liquid biopsies in central nervous system tumors.  Translational Oncology  41, 101881 (2024).
15. Kumar, P., Gupta, S. & Das, B. C. Saliva as a potential non-invasive liquid biopsy for head and neck cancer.  Translational Oncology  40, 101827 (2024).
16. Sorolla, M. A., Sorolla, A., Parisi, E. et al. Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions.  Cancers  13, 2798 (2021).
17. Lee, J. S., Park, S. S., Lee, Y. K. et al. Liquid biopsy using pleural effusion supernatant for EGFR genotyping in lung adenocarcinoma.  BMC Cancer  18, 1236 (2018).
18. Wang, X., Li, Y., Zhang, T. et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy.  Frontiers in Oncology  14, 1303335 (2024).
19. Armakolas, A., Kotsari, M. & Koskinas, J. Liquid Biopsies, Novel Approaches and Future Directions.  Cancers  15, 1579 (2023).
20. Adhit, K. K., Wanjari, A., Menon, S. et al. Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis.  Cureus  15, e50176 (2023).
21. Porta, C., Betti, M., Malapelle, U. et al. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population.  Lung Cancer  185, 107359 (2023).
22. Noor, J., Chaudhry, A., Noor, R. et al. Advancements and Applications of Liquid Biopsies in Oncology.  Cureus  15, e42731 (2023).
23. Huang, H. & Li, H. Tumor heterogeneity and liquid biopsy in bladder cancer.  Cancer Communications  41, 91–108 (2021).
24. Wang, W., He, Y., Yang, F. et al. Current and emerging applications of liquid biopsy in pan-cancer.  Translational Oncology  34, 101720 (2023).
25. Russano, M., Napolitano, A., Ribelli, G. et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors.  Journal of Experimental & Clinical Cancer Research  39, 95 (2020).
26. Goodsaid, F. M. The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics.  Clinical and Translational Science  12, 431–439 (2019).
27. Sisson, B. A., Lockwood, C. M., Newcomb, R. D. et al. Technical and Regulatory Considerations for Liquid Biopsy Validation.  Biomarker Insights  14, 1177271919826545 (2019).
28. Law, E. W., Gandhi, S., Kuderer, N. M. et al. Liquid Biopsy: Emergence of an Alternative Cancer Detection Method.  Clinical and Translational Science  13, 845–847 (2020).
29. National Cancer Institute (NIH). Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA Approval. National Cancer Institute. (2020).
30. U.S. Food and Drug Administration (FDA). FDA Approves Liquid Biopsy NGS Companion Diagnostic Test. FDA. (2020).
31. National Cancer Institute (NIH). FDA Approves Blood Tests That Can Help Guide Cancer Treatment. National Cancer Institute. (2020).
32. Liu, R., Ye, X. & Cui, T. Recent Progress of Biomarker Detection Sensors.  Research  2020, 7949037 (2020).
33. Bao, H., Min, L., Bu, F. et al. Recent advances of liquid biopsy: Interdisciplinary strategies.  Interdisciplinary Medicine  1, e20230021 (2023).
34. Dilsiz, N. A comprehensive review on exosome isolation and characterization.  Translational Oncology  50, 102121 (2024).
35. National Cancer Institute (NIH). Pump Up the Volume: Priming Agents Improve Cancer Liquid Biopsies. National Cancer Institute. (2024).
36. Kalligosfyri, P. M., Lamprou, E. & Kalogianni, D. P. Emerging Sensing Technologies for Liquid Biopsy.  Sensors  24, 7902 (2024).
37. Asadi, M., Ghorbani, S. H., Mahdavian, L. et al. Graphene-based hybrid composites for cancer diagnostics.  Journal of Translational Medicine  22, 611 (2024).
38. Bao, Y., Zhang, D., Guo, H. et al. Beyond blood: Advancing liquid biopsy in oncology. Cancer Science115, 1060–1072 (2024).
39. Imai, M., Nakamura, Y. & Yoshino, T. Transforming cancer screening: multi-cancer early detection.  International Journal of Clinical Oncology  30, 180–193 (2025).
40. Bromberg, J. S., Mathew, J. M., Sood, P. et al. Elevation of Donor-derived Cell-free DNA in Kidney Transplant Rejection.  Transplantation  108, 1994–2004 (2024).
41. Duvvuri, B. & Lood, C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases.  Frontiers in Immunology  10, 502 (2019).
42. Zhang, Y., Li, X., Chen, Z. et al. Multimodal fusion of liquid biopsy and CT enhances lung cancer diagnosis.  npj Precision Oncology  8, 50 (2024).
43. Aziz, Z., Kansal, A., Li, S. et al. Cost-Effectiveness of Liquid Biopsy for Colorectal Cancer Screening.  JAMA Network Open  6, e2343392 (2023).